In the medical device industry, one absolute—which shows no signs of abating—is the need to maintain documentation.

When you peel back the layers of causes leading to serious FDA enforcement action, it comes down to a handful of fundamental reasons.

The FDA says that investigational review boards (IRBs) aren’t required to collect a statement of investigator assurance from studies they preside over.